Literature DB >> 21440199

Biomarkers in the critically ill patient: C-reactive protein.

Jean-Louis Vincent1, Katia Donadello, Xavier Schmit.   

Abstract

Levels of C-reactive protein (CRP), an acute phase protein, are elevated in many inflammatory conditions and are used to detect and follow disease in many fields of medicine, including rheumatology, gastroenterology, and cardiology. CRP concentrations are also used in critically ill patients, notably because they are increased during the inflammatory response to infection, that is, sepsis. However, CRP is not specific for sepsis, and serum CRP concentrations need to be interpreted in the context of a full clinical examination and the presence of other signs and symptoms of sepsis.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21440199     DOI: 10.1016/j.ccc.2010.12.010

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  28 in total

1.  Significantly higher procalcitonin levels could differentiate Gram-negative sepsis from Gram-positive and fungal sepsis.

Authors:  Helena Brodská; Karin Malíčková; Václava Adámková; Hana Benáková; Markéta Marková Šťastná; Tomáš Zima
Journal:  Clin Exp Med       Date:  2012-05-27       Impact factor: 3.984

2.  Usefulness of suPAR in the risk stratification of patients with sepsis admitted to the emergency department.

Authors:  Ivo Casagranda; Chiara Vendramin; Tiziana Callegari; Matteo Vidali; Alessandra Calabresi; Giovanna Ferrandu; Gianfranco Cervellin; Mario Cavazza; Giuseppe Lippi; Isabella Zanotti; Sophie Negro; Andrea Rocchetti; Carlo Arfini
Journal:  Intern Emerg Med       Date:  2015-07-09       Impact factor: 3.397

3.  Substantially elevated C-reactive protein (CRP), together with low levels of procalcitonin (PCT), contributes to diagnosis of fungal infection in immunocompromised patients.

Authors:  Markéta Marková; Helena Brodská; Karin Malíčková; Veronika Válková; Petr Cetkovský; Michal Kolář; Martin Haluzík
Journal:  Support Care Cancer       Date:  2013-05-28       Impact factor: 3.603

4.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

Review 5.  Clinical application of sepsis biomarkers.

Authors:  Vinoth Sankar; Nigel R Webster
Journal:  J Anesth       Date:  2012-10-30       Impact factor: 2.078

Review 6.  Biomarkers as outcome predictors in subarachnoid hemorrhage--a systematic review.

Authors:  Caron M Hong; Cigdem Tosun; David B Kurland; Volodymyr Gerzanich; David Schreibman; J Marc Simard
Journal:  Biomarkers       Date:  2014-02-05       Impact factor: 2.658

7.  Soluble receptor for advanced glycation end products predicts 28-day mortality in critically ill patients with sepsis.

Authors:  Helena Brodska; Karin Malickova; Jiri Valenta; Anthony Fabio; Tomas Drabek
Journal:  Scand J Clin Lab Invest       Date:  2013-10-28       Impact factor: 1.713

Review 8.  suPAR as a prognostic biomarker in sepsis.

Authors:  Katia Donadello; Sabino Scolletta; Cecilia Covajes; Jean-Louis Vincent
Journal:  BMC Med       Date:  2012-01-05       Impact factor: 8.775

9.  The Prognostic Value of suPAR Compared to Other Inflammatory Markers in Patients with Severe Sepsis.

Authors:  Anna Gustafsson; Lennart Ljunggren; Mikael Bodelsson; Ingrid Berkestedt
Journal:  Biomark Insights       Date:  2012-04-10

10.  Pancreatic stone protein as an early biomarker predicting mortality in a prospective cohort of patients with sepsis requiring ICU management.

Authors:  Yok-Ai Que; Frederik Delodder; Idris Guessous; Rolf Graf; Martha Bain; Thierry Calandra; Lucas Liaudet; Philippe Eggimann
Journal:  Crit Care       Date:  2012-07-02       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.